Loading news...
Acuitas Investments LLC lessened its stake in KORU Medical Systems, Inc. (NASDAQ: KRMD) by 53.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 185,353 shares of the company's stock after selling 217,141 shares during the period. Acuitas Investments LLC
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company received U.S. Food and Drug Administration (FDA) clearance for use of the KORU Medical FreedomEDGE® infusion system to deliver RYSTIGGO® (rozanolixizumab-noli), a therapy comme.
KORU Medical Systems, Inc. (KRMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
KORU Medical Systems (NASDAQ: KRMD - Get Free Report) and Patient Portal Technologies (OTCMKTS:PPRG - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability. Earnings and Valuation This table compares
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced preliminary unaudited results for the fourth quarter and full year ended December 31, 2025. Financial Results (unaudited) Preliminary, unaudited fourth quarter 2025 net revenues expected to be $10.9.
TransMedics, KORU Medical Systems and Cardinal Health beat the S&P 500 as execution, earnings visibility and company-specific catalysts drove gains.
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced inducement equity awards to Eric Schiller, Chief Technology Officer, pursuant to his previously announced employment agreement with the Company dated as of December 11, 2025. Mr. Schiller was g.
KORU Medical filed a 510(k) to use FreedomEDGE for subcutaneous PHESGO delivery, expanding into oncology and simplifying breast cancer care.
KORU Medical Systems (NASDAQ: KRMD - Get Free Report) and Movano (NASDAQ: MOVE - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings. Volatility and Risk KORU Medical Systems has
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced the submission of a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) seeking clearance for the use of KORU Medical's FreedomEDGE® infusion system to subcutaneously a.
Albion Financial Group UT trimmed its position in shares of KORU Medical Systems, Inc. (NASDAQ: KRMD) by 39.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 216,374 shares of the company's stock after selling 140,000 shares during the period. Albion Financial
P3 Health Partners (NASDAQ: PIII - Get Free Report) and KORU Medical Systems (NASDAQ: KRMD - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation. Risk and Volatility P3 Health
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on developing, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced the appointment of Eric Schiller as Chief Technology Officer, effective December 29, 2025. Eric joins KORU Medical with more than 25 years of leadership experience across research & development,.
Veeva Systems (NYSE: VEEV - Get Free Report) and KORU Medical Systems (NASDAQ: KRMD - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk. Analyst Recommendations This is a breakdown of
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will present its latest research at the ESID/EHA/SIOPE Focused Symposium 2025 in Vienna, Austria, November 18-20. The poster presentation, titled “Comparing Mechanical Pump and Manual Push for Short-Duration Subcutaneous Infusions: A.
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will be participating in three upcoming Investor Conferences. KORU Medical's management team is participating at the 16th Annual Craig-Hallum Alpha Select Conference on Tuesday, Nove.
KORU Medical Systems, Inc. ( KRMD ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Linda Tharby - President, CEO & Director Tom Adams - CFO, Secretary & Treasurer Conference Call Participants Louisa Smith - Gilmartin Group LLC Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Caitlin Cronin - Canaccord Genuity Corp., Research Division Joseph Downing - Piper Sandler & Co., Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Presentation Operator Greetings, and welcome to KORU Medical Systems Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note, this conference is being recorded.
KORU Medical Systems, Inc. (KRMD) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.03 per share a year ago.
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the third quarter ended September 30, 2025. Recent Highlights • Third quarter 2025 net revenues of $10.4 million, a 27% increase over the prior year period • Core business (Dom.
MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use patient-centric large volume subcutaneous infusion solutions, today announced a development agreement with a global pharmaceutical company. The agreement allows for broad collaboration on next-generation infusion systems in subcutaneous immunoglobulin (SCIg).